Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377429 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
A Phase 2 study, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00377429 is a Phase 2 study that has completed, run by Neovii Biotech. The registered enrollment target is 47 participants.
The verdict
NCT00377429, a Phase 2 study, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete response to chemotherapy.
Interventions
- DRUG catumaxomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377429
The ClinicalTrials.gov registry entry for NCT00377429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neovii Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which catumaxomab is the first listed.
NCT00377429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00377429 about?
NCT00377429 is a clinical study titled "Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy". The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete response to chemotherapy.
What is the current status of trial NCT00377429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2006-09. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00377429?
The interventions under investigation include: catumaxomab (DRUG).
Who is sponsoring clinical trial NCT00377429?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.